Tackling Wasteful Spending on Health
Hide / Show Abstract

Tackling Wasteful Spending on Health

Following a brief pause after the economic crisis, health expenditure is rising again in most OECD countries. Yet, a considerable part of this health expenditure makes little or no contribution to improving people's health. In some cases, it even results in worse health outcomes. Countries could potentially spend significantly less on health care with no impact on health system performance, or on health outcomes. This report systematically reviews strategies put in place by countries to limit ineffective spending and waste. On the clinical front, preventable errors and low-value care are discussed. The operational waste discussion reviews strategies to obtain lower prices for medical goods and to better target the use of expensive inputs. Finally, the report reviews countries experiences in containing administrative costs and integrity violations in health.

Click to Access: 
    http://oecd.metastore.ingenta.com/content/8116241e.pdf
  • PDF
  • http://oecd.metastore.ingenta.com/content/812016241f1.epub
  • ePUB
  • http://www.keepeek.com/Digital-Asset-Management/oecd/social-issues-migration-health/tackling-wasteful-spending-on-health_9789264266414-en
  • READ
 
Chapter
 

Reducing ineffective health care spending on pharmaceuticals You do not have access to this content

English
Click to Access: 
    http://oecd.metastore.ingenta.com/content/8116241ec007.pdf
  • PDF
  • http://www.keepeek.com/Digital-Asset-Management/oecd/social-issues-migration-health/tackling-wasteful-spending-on-health/reducing-ineffective-health-care-spending-on-pharmaceuticals_9789264266414-7-en
  • READ
Author(s):
Karolina Socha-Dietrich, Chris James, Agnès Couffinhal

Hide / Show Abstract

This chapter focuses on opportunities to spend less on pharmaceuticals and other medical supplies. It starts with a discussion of perhaps the most intuitive case of waste, which occurs when prescribed pharmaceuticals (and other medical goods) are discarded unused. Next, the chapter proceeds to the foregone opportunities associated with not substituting originator drugs with cheaper therapeutic alternatives, such as generics or biosimilars. The final issue explored is whether lower prices for pharmaceuticals and other medical supplies could be obtained with more efficient procurement processes.

 
Visit the OECD web site